Is there a role for extended adjuvant neratinib with pCR after neoadjuvant chemotherapy in triple positive breast cancer?   

The benefit of adjuvant neratinib is generally proportional to the residual risk of recurrence following definitive therapy including HER-targeted adjuvant therapy. In the ExteNET study final efficacy report, the absolute difference in overall survival at 5 years was estimated at 9.1% in 295 patient...